Excluding ancestry‐specific ERG/TMPRSS2 fusion partners, cancer drivers uniquely mutated in Africans included, MFF (eight tumours), FAT4 (7), HTRA3 (7), MC2L2 (6), CHD3 (5), MUC17 (5), and TEC (2), and in Europeans MTCH2 (4) and PAPSS2 (3), representing a longer tail of actionable therapeutic targets for Africans. This evidence concerns the gene TMPRSS2 and neoplasm.